Just an edit on what I wrote yesterday in relation to question 1
I wrote
If regulators deam the requirements for finding a treatment for MRSA (for example) can be expedited in lieu of necessity, then clinical studies/funds will be leveraged towards BTX1801. (that's also my unprofessional mildly sized gut feeling)
That should have been written as
If regulators deem the requirements for finding a treatment for MRSA (for example) can be expedited because of or as a result of necessity, then clinical studies/funds will be leveraged towards BTX1801. (that's also my unprofessional mildly sized gut feeling)
again my interpretation of how it was explained to me and apologies for incorrect notation
cheers
Ann: Completion of Placement, page-25
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
-0.015(3.75%) |
Mkt cap ! $693.8M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.0¢ | 38.3¢ | $2.142M | 5.464M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 718749 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 296399 | 8 |
View Market Depth
| Last trade - 15.10pm 03/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |